Helius Medical Technologies Inc (HSDT) concluded trading on Wednesday at a closing price of $0.32, with 8.86 million shares of worth about $2.83 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -95.49% during that period and on June 25, 2025 the price saw a loss of about -0.31%. Currently the company’s common shares owned by public are about 0.53M shares, out of which, 0.50M shares are available for trading.
Stock saw a price change of 4.97% in past 5 days and over the past one month there was a price change of -92.22%. Year-to-date (YTD), HSDT shares are showing a performance of -97.78% which decreased to -96.77% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.30 but also hit the highest price of $24.00 during that period. The average intraday trading volume for Helius Medical Technologies Inc shares is 5.77 million. The stock is currently trading -78.44% below its 20-day simple moving average (SMA20), while that difference is down -89.75% for SMA50 and it goes to -95.52% lower than SMA200.
Helius Medical Technologies Inc (NASDAQ: HSDT) currently have 0.53M outstanding shares and institutions hold larger chunk of about 77.83% of that.
The stock has a current market capitalization of $0.17M and its 3Y-monthly beta is at 1.01. It has posted earnings per share of -$47.81 in the same period. It has Quick Ratio of 1.13 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for HSDT, volatility over the week remained 4.60% while standing at 28.62% over the month.
Stock’s fiscal year EPS is expected to rise by 92.20% while it is estimated to increase by 74.56% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Noble Capital Markets on March 24, 2021 offering an Outperform rating for the stock and assigned a target price of $20 to it.
